Close
  Indian J Med Microbiol
 

Figure 1: Survival curves of the three PSA groups. (a) Overall survival rate among the three groups. No significant difference was observed among the three groups (P = 0.654). (b) PSA progression-free survival rate in response to initial antiandrogen deprivation therapy among the three groups. Patients in the high PSA level group had significantly high PSA progression (P = 0.037). (c) Overall survival rate after CRPC among the three groups. No significant difference was observed among the three groups (P = 0.283). CRPC: castration-resistant prostate cancer; PSA: prostate-specific antigen.

Figure 1: Survival curves of the three PSA groups. (<b>a</b>) Overall survival rate among the three groups. No significant difference was observed among the three groups (<i>P</i> = 0.654). (<b>b</b>) PSA progression-free survival rate in response to initial antiandrogen deprivation therapy among the three groups. Patients in the high PSA level group had significantly high PSA progression (<i>P</i> = 0.037). (<b>c</b>) Overall survival rate after CRPC among the three groups. No significant difference was observed among the three groups (<i>P</i> = 0.283). CRPC: castration-resistant prostate cancer; PSA: prostate-specific antigen.